PT3226843T - Composições anticancro - Google Patents

Composições anticancro

Info

Publication number: PT3226843T
Authority: PT; Portugal
Prior art keywords: anticancer compositions; anticancer; compositions
Prior art date: 2014-12-05

Application number

PT158203513T

Other languages

English (en)

Original Assignee

Aragon Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-05

Filing date

2015-12-03

Publication date

2021-07-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3226843(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-12-03 Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc

2021-07-07 Publication of PT3226843T publication Critical patent/PT3226843T/pt

Links

230000001093 anti-cancer Effects 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Processes Of Treating Macromolecular Substances (AREA)

PT158203513T 2014-12-05 2015-12-03 Composições anticancro PT3226843T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP14196605		2014-12-05

Publications (1)

Publication Number	Publication Date
PT3226843T true PT3226843T (pt)	2021-07-07

Family

ID=52006907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT158203513T PT3226843T (pt)	2014-12-05	2015-12-03	Composições anticancro

Country Status (34)

Country	Link
US (3)	US10285948B2 (pt)
EP (2)	EP3925598B1 (pt)
JP (1)	JP6830892B2 (pt)
KR (1)	KR102387089B1 (pt)
CN (1)	CN106999432A (pt)
AR (1)	AR102925A1 (pt)
AU (1)	AU2015358497B2 (pt)
CA (1)	CA2969675C (pt)
CL (1)	CL2017001373A1 (pt)
CO (1)	CO2017005574A2 (pt)
CR (1)	CR20170218A (pt)
CY (1)	CY1124504T1 (pt)
DK (1)	DK3226843T3 (pt)
EA (1)	EA201791251A1 (pt)
ES (2)	ES3019912T3 (pt)
HR (1)	HRP20211140T1 (pt)
HU (1)	HUE054935T2 (pt)
IL (1)	IL252325A0 (pt)
LT (1)	LT3226843T (pt)
MA (1)	MA41111B1 (pt)
MD (1)	MD3226843T2 (pt)
MX (1)	MX381829B (pt)
MY (1)	MY192931A (pt)
NI (1)	NI201700068A (pt)
PH (1)	PH12017500979A1 (pt)
PL (1)	PL3226843T3 (pt)
PT (1)	PT3226843T (pt)
RS (1)	RS62421B1 (pt)
SG (1)	SG11201704386VA (pt)
SI (1)	SI3226843T1 (pt)
SM (1)	SMT202100454T1 (pt)
TW (1)	TWI709403B (pt)
UA (1)	UA123538C2 (pt)
WO (1)	WO2016090105A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ744456A (en)	2012-09-26	2019-09-27	Aragon Pharmaceuticals Inc	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
HUE054935T2 (hu)	2014-12-05	2021-10-28	Aragon Pharmaceuticals Inc	Rákellenes készítmények
SG11201704267VA (en)	2014-12-05	2017-06-29	Aragon Pharmaceuticals Inc	Anticancer compositions
US10702508B2 (en)	2017-10-16	2020-07-07	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2020144650A1 (en)	2019-01-10	2020-07-16	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of prostate cancer
KR20210122275A (ko)	2019-01-30	2021-10-08	얀센 파마슈티카 엔.브이.	분자 아형에 기초하여 전립선암을 치료하는 방법
EP3917519A1 (en)	2019-01-30	2021-12-08	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
WO2020239478A1 (en)	2019-05-28	2020-12-03	Pharma Mar, S.A.	Trabectedin for treating sarcomas based on genomic markers
US11723898B2 (en)	2019-11-04	2023-08-15	Aragon Pharmaceuticals, Inc.	Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en)	2020-06-05	2021-12-09	Janssen Pharmaceutica Nv	Methods of treating prostate cancer based on molecular subtypes
WO2022049523A1 (en)	2020-09-04	2022-03-10	Aragon Pharmaceuticals, Inc.	Methods for treating prostate cancer
WO2022195407A1 (en)	2021-03-19	2022-09-22	Aragon Pharmaceuticals, Inc.	Methods for treating prostate cancer
WO2023152611A1 (en)	2022-02-11	2023-08-17	Aragon Pharmaceuticals, Inc.	Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en)	2022-04-26	2023-11-02	Aragon Pharmaceuticals, Inc.	Approved drug products and methods for treating prostate cancer
CN121038790A (zh)	2023-03-16	2025-11-28	拜耳消费者护理股份有限公司	用于治疗激素敏感性前列腺癌生化复发患者的雄激素受体拮抗剂
WO2026052846A1 (en)	2024-09-09	2026-03-12	Synthon B.V.	Pharmaceutical formulation comprising apalutamide

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2132449C (en)	1992-03-31	2002-09-10	Susan E. Barrie	17 - substituted steroids useful in cancer treatment
ES2287971T3 (es)	1997-08-11	2007-12-16	Pfizer Products Inc.	Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
WO2001060410A1 (en)	2000-02-21	2001-08-23	Takeda Chemical Industries, Ltd.	Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
CZ20032225A3 (cs)	2001-02-27	2003-11-12	Astrazeneca Ab	Farmaceutická formulace
EP1381358B1 (en)	2001-04-02	2006-05-03	Astrazeneca AB	Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
TNSN03137A1 (en)	2001-06-22	2005-12-23	Pfizer Prod Inc	PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
SE0103424D0 (sv)	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
BR0307515A (pt)	2002-02-01	2004-12-07	Pfizer Prod Inc	Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
WO2003077827A1 (en)	2002-03-19	2003-09-25	Nippon Shinyaku Co., Ltd.	Process for producing drug solid dispersion
AU2003292509B2 (en)	2003-12-15	2007-08-02	Council Of Scientific And Industrial Research	Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer
SI2656842T1 (sl)	2006-03-27	2016-10-28	The Regents Of The University Of California	Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
MY172424A (en) *	2009-04-03	2019-11-25	Hoffmann La Roche	Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
AU2011218173C1 (en)	2010-02-16	2015-04-16	Aragon Pharmaceuticals, Inc.	Androgen receptor modulators and uses thereof
CN102525876B (zh) *	2010-12-15	2014-03-12	西安力邦医药科技有限责任公司	阿司匹林固体分散体、其制备方法、药物组合物和用途
WO2012174436A1 (en)	2011-06-15	2012-12-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Nuclear receptor modulators and their use for the treatment and prevention of cancer
US20150037407A1 (en)	2012-03-21	2015-02-05	Emphascience, Inc.	Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy
WO2013152342A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Anti-cancer mtor inhibitor and anti-androgen combination
EP2858985B1 (en)	2012-06-07	2018-04-18	Aragon Pharmaceuticals, Inc.	Crystalline forms of an androgen receptor modulator
US10668156B2 (en)	2012-06-22	2020-06-02	Basf Se	Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
MX2015002430A (es)	2012-08-24	2015-06-22	Dow Global Technologies Llc	Acetato-succinatos de hidroxialquilmetilcelulosa.
US9977033B2 (en)	2012-09-11	2018-05-22	The Board Of Regents Of The University Of Texas System	Methods for assessing cancer recurrence
JP6404217B2 (ja)	2012-09-11	2018-10-10	メディベイションプロステイトセラピューティクスエルエルシー	エンザルタミドの製剤
NZ744456A (en) *	2012-09-26	2019-09-27	Aragon Pharmaceuticals Inc	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PL2945628T3 (pl)	2013-01-15	2020-09-21	Aragon Pharmaceuticals, Inc.	Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
WO2014114575A1 (en)	2013-01-22	2014-07-31	F. Hoffmann-La Roche Ag	Pharmaceutical composition with improved bioavailability
US20140287039A1 (en)	2013-03-15	2014-09-25	Iceutica Inc.	Abiraterone Acetate Formulation
WO2014167428A2 (en)	2013-04-10	2014-10-16	Shilpa Medicare Limited	Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
CN105636594A (zh)	2013-08-12	2016-06-01	托凯药业股份有限公司	使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
US9566280B2 (en) *	2014-01-28	2017-02-14	Massachusetts Institute Of Technology	Combination therapies and methods of use thereof for treating cancer
WO2015118015A1 (en) *	2014-02-05	2015-08-13	Lek Pharmaceuticals D.D.	Solid pharmaceutical compositions of androgen receptor antagonists
PT3102595T (pt)	2014-02-06	2019-01-11	Hoffmann La Roche	Proteínas de fusão de interleucina-2 e suas utilizações
TWI803187B (zh)	2014-08-08	2023-05-21	日商中外製藥股份有限公司	包含４環性化合物的非晶質體之固體分散體及製劑
LT3226842T (lt)	2014-12-05	2021-03-25	Aragon Pharmaceuticals, Inc.	Priešvėžinės kompozicijos
HUE054935T2 (hu)	2014-12-05	2021-10-28	Aragon Pharmaceuticals Inc	Rákellenes készítmények
SG11201704267VA (en)	2014-12-05	2017-06-29	Aragon Pharmaceuticals Inc	Anticancer compositions
CA3024872A1 (en) *	2016-06-03	2017-12-07	Aragon Pharmaceuticals, Inc.	Anticancer compositions

2015
- 2015-12-03 HU HUE15820351A patent/HUE054935T2/hu unknown
- 2015-12-03 EP EP21175525.1A patent/EP3925598B1/en active Active
- 2015-12-03 TW TW104140459A patent/TWI709403B/zh not_active IP Right Cessation
- 2015-12-03 MY MYPI2017701986A patent/MY192931A/en unknown
- 2015-12-03 SI SI201531686T patent/SI3226843T1/sl unknown
- 2015-12-03 PT PT158203513T patent/PT3226843T/pt unknown
- 2015-12-03 RS RS20211035A patent/RS62421B1/sr unknown
- 2015-12-03 MX MX2017007206A patent/MX381829B/es unknown
- 2015-12-03 CN CN201580066235.3A patent/CN106999432A/zh active Pending
- 2015-12-03 US US15/533,229 patent/US10285948B2/en active Active
- 2015-12-03 AU AU2015358497A patent/AU2015358497B2/en active Active
- 2015-12-03 WO PCT/US2015/063671 patent/WO2016090105A1/en not_active Ceased
- 2015-12-03 DK DK15820351.3T patent/DK3226843T3/da active
- 2015-12-03 KR KR1020177018243A patent/KR102387089B1/ko active Active
- 2015-12-03 CR CR20170218A patent/CR20170218A/es unknown
- 2015-12-03 EA EA201791251A patent/EA201791251A1/ru unknown
- 2015-12-03 ES ES21175525T patent/ES3019912T3/es active Active
- 2015-12-03 JP JP2017529774A patent/JP6830892B2/ja active Active
- 2015-12-03 MA MA41111A patent/MA41111B1/fr unknown
- 2015-12-03 MD MDE20170154T patent/MD3226843T2/ro not_active IP Right Cessation
- 2015-12-03 EP EP15820351.3A patent/EP3226843B1/en active Active
- 2015-12-03 UA UAA201707015A patent/UA123538C2/uk unknown
- 2015-12-03 SG SG11201704386VA patent/SG11201704386VA/en unknown
- 2015-12-03 SM SM20210454T patent/SMT202100454T1/it unknown
- 2015-12-03 LT LTEP15820351.3T patent/LT3226843T/lt unknown
- 2015-12-03 ES ES15820351T patent/ES2883187T3/es active Active
- 2015-12-03 CA CA2969675A patent/CA2969675C/en active Active
- 2015-12-03 HR HRP20211140TT patent/HRP20211140T1/hr unknown
- 2015-12-03 PL PL15820351T patent/PL3226843T3/pl unknown
- 2015-12-04 AR ARP150103981A patent/AR102925A1/es unknown
2017
- 2017-05-16 IL IL252325A patent/IL252325A0/en unknown
- 2017-05-26 PH PH12017500979A patent/PH12017500979A1/en unknown
- 2017-05-29 CL CL2017001373A patent/CL2017001373A1/es unknown
- 2017-06-02 NI NI201700068A patent/NI201700068A/es unknown
- 2017-06-05 CO CONC2017/0005574A patent/CO2017005574A2/es unknown
2019
- 2019-03-19 US US16/357,821 patent/US11224575B2/en active Active
2021
- 2021-03-15 US US17/201,811 patent/US11911511B2/en active Active
- 2021-08-13 CY CY20211100730T patent/CY1124504T1/el unknown

Also Published As

Publication number	Publication date
US11224575B2 (en)	2022-01-18
US10285948B2 (en)	2019-05-14
US20210308060A1 (en)	2021-10-07
PL3226843T3 (pl)	2021-12-13
CL2017001373A1 (es)	2018-01-05
AU2015358497A1 (en)	2017-06-08
HUE054935T2 (hu)	2021-10-28
KR102387089B1 (ko)	2022-04-14
MX381829B (es)	2025-03-13
RS62421B1 (sr)	2021-10-29
MX2017007206A (es)	2018-01-30
TWI709403B (zh)	2020-11-11
MA41111B1 (fr)	2021-09-30
DK3226843T3 (da)	2021-08-16
LT3226843T (lt)	2021-08-10
CY1124504T1 (el)	2022-07-22
SMT202100454T1 (it)	2021-09-14
EP3925598B1 (en)	2025-02-12
MD3226843T2 (ro)	2021-10-31
NI201700068A (es)	2017-09-11
SG11201704386VA (en)	2017-06-29
BR112017011726A2 (pt)	2017-12-26
US11911511B2 (en)	2024-02-27
EP3226843B1 (en)	2021-05-26
JP2017536407A (ja)	2017-12-07
CR20170218A (es)	2017-08-30
ES2883187T3 (es)	2021-12-07
AR102925A1 (es)	2017-04-05
EP3226843A1 (en)	2017-10-11
IL252325A0 (en)	2017-07-31
HRP20211140T1 (hr)	2021-10-15
PH12017500979A1 (en)	2017-11-27
WO2016090105A1 (en)	2016-06-09
ES3019912T3 (en)	2025-05-21
CN106999432A (zh)	2017-08-01
MY192931A (en)	2022-09-15
EA201791251A1 (ru)	2017-11-30
CO2017005574A2 (es)	2017-09-29
KR20170086658A (ko)	2017-07-26
SI3226843T1 (sl)	2021-11-30
CA2969675A1 (en)	2016-06-09
TW201636019A (zh)	2016-10-16
EP3925598A1 (en)	2021-12-22
UA123538C2 (uk)	2021-04-21
CA2969675C (en)	2023-06-06
AU2015358497B2 (en)	2021-04-29
US20170360713A1 (en)	2017-12-21
US20190209477A1 (en)	2019-07-11
JP6830892B2 (ja)	2021-02-17

Publication	Publication Date	Title
IL279833A (en)	2021-01-31	Anti-cancer drugs
IL252324A0 (en)	2017-07-31	Anti-cancer drugs
IL252325A0 (en)	2017-07-31	Anti-cancer drugs
GB201419257D0 (en)	2014-12-10	Pharmaceutical compositions
GB201618482D0 (en)	2016-12-14	Pharmaceutical compositions
IL249553A0 (en)	2017-02-28	Pharmaceutical preparations
IL263157A (en)	2018-12-31	Anticancer compositions
GB201403017D0 (en)	2014-04-09	Composition
GB201703061D0 (en)	2017-04-12	Polyphenol compositions
GB201408167D0 (en)	2014-06-25	Compositions
IL251479A0 (en)	2017-05-29	components
IL250817A0 (en)	2017-04-30	pharmaceutical preparations
GB201420306D0 (en)	2014-12-31	Compositions
GB201410493D0 (en)	2014-07-30	Composition
GB201404390D0 (en)	2014-04-23	Composition
GB201403550D0 (en)	2014-04-16	Composition
GB201402648D0 (en)	2014-04-02	Composition
GB201419849D0 (en)	2014-12-24	Compositions
GB201406863D0 (en)	2014-05-28	Compositions comprising variegin
GB201415634D0 (en)	2014-10-22	Novel compositions
HUE036695T2 (hu)	2018-07-30	Ubidekarenon készítmény
GB202009707D0 (en)	2020-08-12	Anti-adherant botanical compositions
SG2014014872A (en)	2014-08-28	Pharmaceutical compositions
GB201408432D0 (en)	2014-06-25	Pharmaceutical compositions
GB201402487D0 (en)	2014-03-26	Composition